Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal

Area of Science:

• Virology
• Genomics
• Pharmacology

Background:

• The 21st century has seen multiple zoonotic coronavirus outbreaks, including the ongoing COVID-19 pandemic caused by SARS-CoV-2.
• Diverse therapeutic strategies for COVID-19 are under investigation, but effective treatments are still needed.
• The global impact of SARS-CoV-2 necessitates urgent development of accessible treatment options.

Purpose of the Study:

• To identify repurposable drug candidates for treating COVID-19 using a systems biology approach.
• To leverage large-scale transcriptomic datasets to find potential therapeutic interventions.
• To accelerate the discovery of effective treatments for SARS-CoV-2 infection.

Main Methods:

• Utilized the largest available dataset of drug-induced transcriptomic perturbations.
• Analyzed public SARS-CoV-2 transcriptomic datasets and normal lung expression profiles.
• Employed an unbiased systems biology approach to prioritize drug candidates.

Main Results:

• Prioritized over 50 drug candidates with repurposing potential for COVID-19 treatment.
• Identified drug classes including corticosteroids and kinase inhibitors (Janus kinase, Bruton kinase).
• The findings provide a foundation for further clinical investigation of these candidates.

Conclusions:

• The identified drug candidates represent promising therapeutic options for COVID-19.
• Further clinical investigation of these FDA-approved drugs, alone or in combination with antivirals like remdesivir, is warranted.
• This research offers a data-driven strategy to expedite the development of effective COVID-19 therapies.